Eli Lilly: Lilly Endowment reports 9.6% stake
The reported 9.6% interest was calculated against 941,357,065 Eli Lilly shares outstanding as of August 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly and Company (LLY) reporting person Lilly Endowment, Inc. reported beneficial ownership of 90,066,978 common shares, or 9.6%, as of September 30, 2026. Lilly Endowment reported sole voting power and sole dispositive power over all 90,066,978 shares, with no shared voting or dispositive power.
The percentage is based on 941,357,065 Eli Lilly shares outstanding as of August 3, 2026. None of Lilly Endowment’s shares were deemed beneficially owned through a right to acquire shares.
Key Figures
Key Terms
beneficially owned regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of LLY does Lilly Endowment own?
AI-generated analysis. How Rhea-AI works. Not financial advice.